Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

-License, collaboration, and other

6,4767,827Total revenue

23,00417,949Operating costs and expenses:Cost of goods sold

11,6618,707Research and development

45,61835,085General and administrative

11,12910,414Impairment of long-lived assets

-1,675Total operating costs and expenses

68,40855,881Loss from operations

(45,404)(37,932)Non-operating income (expense):Interest income 

314632Interest expense

(4,645)(2,548)Non-cash interest expense on liability related to sale of future royalties

(5,543)(1,785)Other income (expense), net

427660Total non-operating expense, net

(9,447)(3,041)Loss before provision for income taxes

(54,851)(40,973)Provision for income taxes

212124Net loss

$ (55,063)$ (41,097)Basic and diluted net loss per share

$
(0.48)$
(0.36)Weighted average shares used in computing basic and diluted net loss per share

115,309114,531 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Three Months Ended March 31,20132012Cash flows from operating activities:Net loss 

$(55,063)$ (41,097)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on liability related to sale of future royalties 

5,5431,785Non-cash royalty revenue related to sale of future royalties

(4,393)-Stock-based compensation 

4,2454,234Depreciation and amortization 

3,6283,510Impairment of long-lived assets 

-1,675Other non-cash transactions

139295Changes in operating assets and liabilities:Accounts receivable 

2,158(5,865)Inventory

(112)(1,452)Other assets 

3,8444,305Accounts payable 

1,355(1,290)Accrued compensation 

179(4,620)Accrued expenses 

(1,130)1,094Accrued clinical tri
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Houston dentist , Dr. ... treatment with Invisalign. With access to this increasingly ... teeth straightened without feeling self-conscious in the process. ... other types of braces, but patients who choose ... to better support for their oral health and ...
(Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... prodotti per la cura dei disturbi respiratori del sonno ... avuto un,ingiunzione permanente in Germania contro il produttore Taiwanese ... la vendita di apparecchiature da indossare in testa, che ... le maschere 220. La sentenza della Corte Regionale Distrettuale ...
(Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
Breaking Medicine Technology:Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
(Date:7/28/2014)... America Carotenoids & Antioxidants Market report defines and segments the ... forecast of revenue. This market is estimated to grow from ... at a CAGR of 7.1% from 2013 to 2018. , ... Antioxidants Market report to get an idea of the in-depth ... in the market, and is supported by various tables and ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- People with ... for obesity and diabetes, a new study suggests. ... that brown fat actually improves insulin sensitivity, blood sugar ... for overweight and obese people," Labros Sidossis, a professor ... at the University of Texas Medical Branch at Galveston, ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
... Dental Service Building for Early Childhood Oral Health at ... to provide 30,000 patient visits annually, SEATTLE, Nov. ... and Children,s Hospital and Regional Medical Center,today announced they ... dental disease with the development of a new pediatric ...
... and Reject ... Ramius, Opposition Slate, MONTVALE, ... mailed the following letter to all shareholders from,Lawrence Saper, Chairman ... Company,s Annual Meeting of Shareholders scheduled for,Thursday, December 20, 2007. ...
... Wash., Nov. 16 CellCyte Genetics,Corporation (the ... Tony,Colasin as its Director of Business Development ... licensing efforts. Tony Colasin was former ... From January 2001 to January 2007, he ...
... gave up as he,battled corporate investors as they took over ... him about greed and ethics,"isn,t the kind of thing you ... education to good use, pulling together an,experienced management team this ... juice drink for school-aged children. As co-founder and CEO ...
... Neutrogena(R), a worldwide leader,in the development of highly ... Diane Lane has signed on to be,an ambassador ... captivating and inspiring actress who personifies the,Neutrogena(R) brand ... her new,role, she will be featured in national ...
... rate between 0 and 2.6% (average 0.3%) in general population. ... tolerated by patients, causing a delay in medical consultation. Together ... with diagnosis and treatment of tinea of the nails. , ... the nails was observed in the Hospital del Mar Pediatric ...
Cached Medicine News:Health News:$5 M Gift Boosts Childhood Oral Health Care Offered by UW, Children's Hospital 2Health News:Datascope Mails Letter to Shareholders 2Health News:Datascope Mails Letter to Shareholders 3Health News:Datascope Mails Letter to Shareholders 4Health News:Datascope Mails Letter to Shareholders 5Health News:Datascope Mails Letter to Shareholders 6Health News:Datascope Mails Letter to Shareholders 7Health News:Datascope Mails Letter to Shareholders 8Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 2Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 3Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 4Health News:Fruit 66 Creator Takes the High Road to Create a Healthy Drink for Students 2Health News:Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador 2Health News:Tinea of the nails underdiagnosed in children 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: